(Q33966333)

30 July 2017

1 reference

title

Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes (English)

1 reference

30 July 2017

0 references

0 references

0 references

0 references

1 reference

Raza A

1

1 reference

30 July 2017

1 August 2000

1 reference

Microscopy Research and Technique

30 July 2017

1 reference

30 July 2017

50

1 reference

30 July 2017

229-235

1 reference

30 July 2017

3

1 reference

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

30 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Sepsis and cytokines: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Tumour necrosis factor in synovial exudates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Role of cytokines in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Review article: safety of infliximab in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Preconditioning: can nature's shield be raised against surgical ischemic-reperfusion injury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Current status of clinical trials with anti-TNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

T cells in inflammatory bowel disease: protective and pathogenic roles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Review article: the efficacy of infliximab in Crohn's disease--healing of fistulae

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Angiogenesis in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Initial transforming event in myelodysplastic syndromes may be viral: case for cytomegalovirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Consilience across evolving dysplasias affecting myeloid, cervical, esophageal, gastric and liver cells: common themes and emerging patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

New strategies in the management of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0029%2820000801%2950%3A3%3C229%3A%3AAID-JEMT6%3E3.0.CO%3B2-H

10.1002/1097-0029(20000801)50:3<229::AID-JEMT6>3.0.CO;2-H

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10891888